TOGETHER.
Reporter: DEBRA ALFARONE,
CBS NEWS, THE WHITE HOUSE.
ANOTHER CORONAVIRUS VACCINE
HAS BEGUN, IT IS PHASE THREE
CLINICAL TRIAL, THE LAST STAGE
FOUR APPROVAL.
ASTRAZENECA SAYS IT IS
ENROLLING 30,000 AMERICANS IN
THE LATE STAGE CLINICAL TRIAL
AND ANOTHER 20,000 OUTSIDE THE
COUNTRY.
PARTICIPANTS WILL RECEIVE TWO
ACTIVE, OR TWO PLACEBO DOSES
SPACED FOUR WEEKS APART.
THE APPROVAL PROCESS NORMALLY
TAKES MONTHS, IF NOT YEARS, BUT
THE FDA COMMISSIONER SAYS IF
THERE IS ENOUGH DATA FROM PHASE
THREE TRIALS EARLY,
AUTHORIZATION COULD BE
POSSIBLE.
A LOT OF PEOPLE COUNT ON THAT.
RESEARCHERS AT OXFORD
UNIVERSITY IN PARTNERSHIP WITH
ASTRAZENECA, STARTED DOSING THE
FIRST VOLUNTEERS IN THE STATE
OF FLORIDA ON FRIDAY.
DR. JOHN SPOKE EXCLUSIVELY
WITH THE FIRST AMERICAN IN THE
TRIAL.
Reporter: 23-YEAR-OLD, JACOB
SERRANO, IS THE FIRST WANTS
YEAR TO BE DIAGNOSED IN THE
U.S. HE HAS LOST SEVEN FAMILY
MEMBERS TO COVID-19 AND SAYS HE
WANTS TO BE A PART OF THE
SOLUTIONS TO SAVE LIVES NO
MATTER THE COST.
I KNEW THERE WAS A RISK,
BECAUSE, LIKE, IT IS A TRIAL,
BUT I WANT WOULD RATHER HAVE US
ONE STEP CLOSER, NO MATTER WHAT
IT TAKES.
IMMUNE RESPONSE IS VERY
ENCOURAGING.
Reporter: HE SAYS HE IS
OPTIMISTIC THIS VACCINE IS
AFFECTED.
IN THE PHASE ONE AND TWO
TRIALS, THE VACCINE HAS BEEN
IMPROVING, NOT ONLY ARE WE
GOING TO GET ROBUST
NEUTRALIZING ANTIBODIES TO
FIGHT THE CORONAVIRUS, YOU GET
A T CELL RESPONSE TO FIGHT OFF
THE CELLS THAT DO BECOME
INFECTED.
THAT IS DRIZZLE IN CRUDE
TREATING INFECTIONS.
Reporter: IN EARLIER PHASES,
THERE IS NO EVIDENCE THE
VACCINE HAS CAUSED SERIOUS
REACTIONS.
HEADLANDS RESEARCH SAYS THEY
ARE FOCUSED ON MINORITY
COMMUNITIES THOSE WHO HAVE BEEN
IMPACTED BY THE PANDEMIC.
THAT IS A GROUP THAT COULD
HIGHLY BENEFIT FROM
VACCINATION.
Reporter: ASTRAZENECA SAYS
IT PLANS TO ROLLOUT GLOBAL
